Delivering the Results in Drug-Based Nanotechnology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Delivering the Results in Drug-Based Nanotechnology
New nanotechnology-based delivery systems offer promise in drug delivery, particularly for anticancer therapeutics.


Pharmaceutical Technology
Volume 33, Issue 10, pp. 54-56


Patricia Van Arnum
Drug delivery dominates the use of nanotechnology in pharmaceuticals. Applications include organic nanoplatforms such as polymers, lipids (e.g., liposomes, nanoemulsions, and solid–lipid nanoparticles), self-assembling structures, and dendrimers as well as certain inorganic nanoplatforms including metal (e.g., gold and silver), and silica-based nanostructures (1).

Setting the framework

The US Food and Drug Administration has not established its own formal definition of nanotechnology, although the agency participated in a definition of nanotechnology set by the National Nanotechnology Initiative (NNI). The NNI is a federal research and development (R&D) program established to coordinate the multiagency efforts in nanoscale science, engineering, and technology. FDA and 22 other federal agencies participate. The NNI defines nanotechnology to involve all of the following criteria:

  • Research and technology development at the atomic, molecular, or macromolecular levels, in the length scale of approximately 1–100 nm range
  • Creating and using structures, devices, and systems that have novel properties and functions because of their small and/or intermediate size
  • Ability to control or manipulate on the atomic scale (1).


ROBERT KOHLHUBER, SOUTHERN STOCK/GETTY IMAGES
Using that definition, nanotechnology relevant to FDA may include R&D that would satisfy the NNI definition and relate to a product regulated by FDA (2). The specific regulatory requirments, including safety and related issues, are still under consideration. To gain input on these matters, FDA held a public meeting in September 2008. Earlier this year, FDA launched a public–private partnership with the Alliance for NanoHealth and eight academic institutions for purposes of expanding knowledge of how nanoparticles behave and affect biologic systems. The alliance hopes to facilitate the development of tests and processes that might mitigate the risks associated with nanoengineered products.

Nanodrugs in action

Although the regulatory framework for nanotechnology in pharmaceutical applications and its exact definition are under consideration, in the context of technology platforms, a broader term of nanodrugs may be used. These nanomedicines are drugs that use platforms based on nanotechnology and related approaches. The technology evolution of nanodrugs can be seen when evaluating commercial products and clinical and preclinical candidates.

"In the current nanotechnology drug market, the strategy is largely on product-life extension by formulating existing drugs to enhance their half-lives, improve their oral bioavailability, or efficacy," says Lee Jia, senior project officer of the Developmental Therapeutics Program for the National Cancer Institute at the National Institutes of Health, who spoke at the 2008 American Association of Pharmaceutical Scientists annual meeting. Advanced nanotechnology systems such as dendrimers and carbon nanotubes are not yet represented in the list of approved nanodrugs. Unlike the majority of clinical and preclinical nanodrugs, only 25% of currently marketed nanodrugs are directed toward cancer treatment (3).


Nanoparticles as vaccine adjuvants.
There are approximately 28 approved nanodrugs on the market. These drugs primarily use liposomes, polymers, and nanocrystallines as the basis of formulations. Twelve of these drugs use a liposomal drug-delivery system, 10 a polymeric-based system (such as pegylation), and 5 nanocrystalline systems. Other systems include albumin-bound platforms (3).

When examining the nanodrugs in clinical development, more advanced systems are used, and there is a greater emphasis on anticancer therapeutics (2). Although liposomal and polymeric-based platforms are still represented, more complex systems such as nanocrystals, nanoemulsions, drugs formulated with gold nanoparticles, and dendrimers are used. Gold nanoparticles, for example, use the leaky vasculatures of tumors to target delivery of pharmaceutically active compounds to the tumor. Dendrimers, which have high loading power and specific targeting units, can deliver more active compounds to specific organs and tissues. There are at least 27 nanodrugs in clinical trials, and approximately 60% of them are for cancer treatment (3).

The value-added focus on nanotechnology in drug development is pushed further in preclinical drug candidates. There are at least 23 nanodrugs in preclinical development, and 78% of them are anticancer agents. New formulations involve the use of dendrimers and metallic, ceramic, and virus-based nanoparticles (3).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here